Envestnet Asset Management
MCRB icon

Envestnet Asset Management’s Seres Therapeutics MCRB Stock Holding History

Envestnet Asset Management’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-673
Closed -$321K – 3724
2021
Q2 		$321K Buy
673
+36
+6% +$15.2K ﹤0.01% 3243
2021
Q1 		$263K Buy
+637
New +$293K ﹤0.01% 3209

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Envestnet Asset Management's MCRB Position: Q3 2021 in Review

Envestnet Asset Management sold out of Seres Therapeutics (MCRB) in Q3 2021, closing a stake of 673 shares — an estimated $321K sold.

Envestnet Asset Management first reported a position in MCRB in Q1 2021 and held it in 2 quarters. The position peaked at $321K in Q2 2021. 133 funds tracked by Wall St. Rank hold MCRB as of Q3 2021.

  • Envestnet Asset Management reported no remaining Seres Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Envestnet Asset Management sold 673 Seres Therapeutics shares in Q3 2021, an estimated $321K.
  • Envestnet Asset Management first reported a position in Seres Therapeutics in Q1 2021 and held it in 2 quarters.
  • Envestnet Asset Management's Seres Therapeutics position peaked at $321K in Q2 2021.
  • 133 funds tracked by Wall St. Rank held Seres Therapeutics as of Q3 2021.

Based on Envestnet Asset Management's 13F filing for Q3 2021, filed 7 Oct 2021.